咪唑立宾(mizoribine,MZR)是1971年从霉菌E2upenicillum brefeldianum的培养液中分离而得的一种咪唑类核苷,是一种新型免疫抑制剂,能特异性地抑制快速增长的淋巴细胞,如T细胞、B细胞的分裂和增殖,从而产生免疫抑制作用。1984年日本政府批准其作为一种免疫抑制剂用于治疗肾移植的排斥反应,之后,也被用于类风湿关节炎和激素抵抗的肾病综合征。近年来,在治疗狼疮性肾炎、多种硬化性疾病方面也有较多应用。本文将对咪唑立宾在肾脏疾病治疗中的作用进行综述。 Mizoribine (MZR), an imidazole nucleoside isolated from the culture of mold strain E2upenicillum brefeldianum in 1971, is a novel immunosuppressant that specifically inhibits rapidly growing lymphocytes such as T cells, B cell division and proliferation, resulting in immunosuppressive effects. In 1984, the Japanese government approved its use as an immunosuppressive agent in the treatment of renal allograft rejection and later in rheumatoid arthritis and hormone resistance nephrotic syndrome. In recent years, in the treatment of lupus nephritis, a variety of sclerosing diseases also have more applications. This article reviews the role of midazolam in the treatment of kidney disease.